ValuentumAd

Official PayPal Seal
Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Latest Valuentum Commentary

Mar 20, 2015
Hooray! Biogen’s Breakthrough Alzheimer’s Drug?
Biogen’s potential new drug could help millions of people suffering from Alzheimer’s.
Feb 7, 2015
A Meaningful Rate Hike? No Way
REIT investors are getting spooked by a strong jobs report. Ahhh – when good news is bad news again.
Jan 9, 2015
January 5-9: The Week That Was - Drowning in Crude
Let’s cover new developments during the first week of 2015.
Oct 15, 2014
Johnson & Johnson: Still a Solid Dividend Growth Pick
We have no plans to remove Johnson & Johnson from the Dividend Growth portfolio.
Oct 15, 2014
The Correction: Markets Collapse! Ebola Fears!
The equity markets have been rocked.
Oct 13, 2014
Performance of the Valuentum Buying Index
Two separate studies have reinforced the efficacy of the Valuentum Buying Index, both as a portfolio optimization tool and as an idea generator. Let's get the thoughts of Valuentum's Brian Nelson on the studies.
Sep 3, 2014
Performance Update: The Valuentum Buying Index
Let’s take a look at how the Valuentum Buying Index has performed.
Aug 1, 2014
Markets Collapse: Economic Sanctions on Russia, Argentina Defaults…Again
Dow Jones falls over 300 points Thursday on Argentina default and economic sanctions on Russia. The very idea that we don’t know which hedge funds will be hurt by recent global economic activity, how leveraged these hedge funds are to global currencies and equities, and whether Russian president Vladimir Putin will respond in kind to economic sanctions means conservative investors are taking money off the table. Is it finally time to lock in profits after one of the best stock-market runs of all time from the March 2009 lows?
Jul 30, 2014
Big Pharma Round Up
Let’s take a look at recent quarterly results from Big Pharma.


Latest News and Media
The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.